JPMorgan Starts Dyne Therapeutics (DYN) at Overweight
- Wall Street ends first day of third quarter with solid rebound
- Goldman Sachs Warns Clients of More Equity Market Losses in Second Half of 2022
- Kohl's (KSS) Falls 15% After Ending Sale Talks With Franchise Group and Issuing Q2 Warning
- General Motors Warns It Has 95k Vehicles in Inventory Without Certain Components
- FAAMG Stocks Fall 32% on Average During 1st-Half of 2022
JPMorgan initiates coverage on Dyne Therapeutics (NASDAQ: DYN) with a Overweight rating and a price target of $27.00.
Shares of Dyne Therapeutics closed at $18.64 yesterday.
You May Also Be Interested In
- UPDATE: Citi Starts Symbotic Inc. (SYM) at Buy
- UPDATE: Citi Starts Sonoco Products (SON) at Buy, 'Improved but Unloved, with Added Defense at the Right Time'
- UPDATE: H.C. Wainwright Starts Theseus Pharmaceuticals Inc. (THRX) at Buy
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!